Navigation Links
Selexis Now Offering Rapid-Development of Human Cell Line With FDA Approval Pedigree
Date:7/16/2008

New contract service offering rapid development of high performance HEK293 (human) production cell lines enabled by Selexis Genetic Elements(TM) and

Selexis SURE(TM) Cell Line Development program

GENEVA, July 16 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company offering DNA based technologies and supportive services to enable significantly improved drug discovery, development, and cGMP production of biologics, announced today it has partnered with the National Research Counsel of Canada's Biological Research Institute (NRC-BRI) to offer the NRC-BRI HEK293 cell technologies for the contract development of high-performance stable human cell lines enabled by the Selexis Genetic Element(TM) and Selexis SURE Cell Line Development(SM) Services.

HEK293 cells are the most widely used HUMAN cell line in biotechnology industry and the ONLY human cell line used for the bioproduction of an FDA approved biopharmaceutical drug.

Xigrils(R), a recombinant form of human Activated Protein C, is marketed by Eli Lilly and Company for the treatment of severe sepsis. Xigrils(R) was approved by US-FDA in November of 2001 and is produced using HEK293 cells.

Dr. Igor Fisch, President and CEO of Selexis, commented:

"Partnering with the NCR-BRI to offer their well characterized human cell line is a perfect complement to our well developed and proven CHO platform, especially considering the fact that HEK293 cells have already been approved for the production of a recombinant protein drug."

"For over a decade Dr. Amine Kamen and his team of researchers at the BRI have done an outstanding job of developing their HEK293 program for large scale production purposes and now Selexis has the opportunity to make it more widely available with improved performance characteristics using our Selexis Genetic Element(TM) technology and our Selexis SURE Cell Line Development(SM) Services."

"This partnership will further reinforces Selexis' position as world leader of DNA-based technologies that significantly improve the long-term and stable expression of transgenes in a variety of eukaryotic host systems."

Dr. Pierre-Alain Girod, CSO of Selexis, commented:

"This combined program will be highly desirable to biotech companies needing the rapid development of a high performance cell line expressing proteins with human glycosylation patterns. This new platform will be a viable option to our CHO program for more difficult to express proteins."

About Selexis HEK293 Services:

Selexis is offering the global biotech market a proven avenue for the rapid development of high-performance HEK293 cell lines prepared under ICH guidelines and ready for cGMP manufacturing. Using the Selexis SURE Cell Line Development program, which is based on the use of the Selexis Genetic Element(TM) technologies, Selexis is now offering the development of stable clonal cell lines in as little as 12 weeks from transfection.

About Selexis:

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services that enables significant improvements in the time, effort and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MABs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of epigenetic DNA based elements that control the dynamic organization of chromatin within all mammalian cells. Application of the Selexis Genetic Elements(TM) using the SURE Cell Line Development process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs.

Xigrils(R) is a registered trademark of Eli Lilly and Company.


'/>"/>
SOURCE Selexis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Exelixis Commences Public Offering of Common Stock
2. Eularis Announces New Corporate Name and Expanded Product Offerings
3. Healthcare Realty Trust Announces Public Offering of Common Stock
4. FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use
5. Volcano Corporation Announces Proposed Public Offering of Common Stock
6. Highlands Acquisition Corp. Completes Initial Public Offering
7. AKELA Pharma Inc. announces U.S. public offering and proposed listing
8. Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast, Ovarian, Uterine or Colorectal Cancer
9. Akron-Canton Airport offering flu shot clinic for 90 days
10. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
11. Arena Pharmaceuticals Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: